All roads lead to migraine

December 16, 2019

London, UK: A recent study published in the journal Cephalalgia, the official journal of the International Headache Society, reported an intriguing discovery. The study, entitled "Investigation of distinct molecular pathways in migraine induction using calcitonin gene-related peptide and sildenafil", was conducted by Dr. Samaira Younis and colleagues from the Danish Headache Center, Rigshospitalet Glostrup, University of Copenhagen, Denmark.

Previous clinical studies from the same research group using experimental human models have shown that at least two cellular signaling pathways are involved in migraine attacks. One is mediated by increases in cyclic adenosine monophosphate (cAMP), which can be stimulated by infusing calcitonin gene-related peptide (CGRP) intravenously in patients, and the other one, the cyclic guanosine monophosphate (cGMP), which is upregulated under the actions of the inhibitor of phosphodiesterase-5 sildenafil. The research question in this study was whether activation of these 2 different signaling pathways would yield distinct migraine attacks with regard their clinical characteristics.

Dr Younis investigated the clinical characteristics of migraine attacks of 27 participants following intravenous injections of CGRP and oral administration of sildenafil. Attacks' pain localization and quality, as well as related symptoms such photophobia, phonophobia, nausea, aggravation by exertion, and triggers associated were compared between conditions in a double-blind, randomized, cross over design. Participants received both CRRP and sildenafil in two different days, separated by approximately 14 day in order to avoid drugs carry-over effect.

CGRP and sildenafil provoked migraine attacks in 67% and 89% of patients, respectively. In 63% of participants, both drugs provoked migraine attacks. There were no differences in the clinical characteristics of attacks, meaning that both drugs act through a redundant molecular pathway. The finding concerning a more effective action of sildenafil in provoking migraine attacks "might be attributed to its more downstream effects, thus being closer to the common determinator compared to CGRP in the migraine initiating cascade", Dr Younis explains. Additionally, The findings of this study will help researchers to search for "commonality of migraine attack initiation as it could prove a prospective cellular target for new preventive therapeutics", Dr Younis concludes.
-end-
Study's link: https://doi.org/10.1177/0333102419861712

Contact Information:

Samaira Younis, Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup Faculty of Health and Medical Sciences, University of Copenhagen, Valdemar Hansens Vej 5, DK-2600 Glostrup, Denmark.

Email: samaira.younis.01@regionh.dk

About Cephalalgia and International Headache Society:Cephalalgia is the official journal published on behalf of the International Headache Society (IHS), which is the world's leading membership organization for those with a professional commitment to helping people affected by headache. The purpose of IHS is to advance headache science, education, and management, and promote headache awareness worldwide.

International Headache Society

Related Sildenafil Articles from Brightsurf:

Seeing blue after the little blue pill: Visual disturbances in Viagra users
Sildenafil, a common treatment for erectile dysfunction, is typically safe with limited side effects.

Long term risks cast further doubt on the use of Viagra for foetal therapy
University of Manchester scientists investigating a possible treatment for foetal growth restriction (FGR), a condition in which babies grow poorly in the womb, have urged further caution on the use of Viagra.

All roads lead to migraine
Dr. Samaira Younis, from the Danish Headache Center in Copenhagen, Denmark, shares her research results, which suggests there are no differences between migraine attacks clinical characteristics following administration of 2 different compounds in patients, CGRP and sildenafil, meaning they share common cellular signaling pathways.

Preeclampsia treatment for mothers also benefits offspring
An estimated six to 15 million people in the US are children born of a pregnancy complicated by preeclampsia.

New discovery provides key to side effects caused by erectile dysfunction drugs
Study reveals several features of PDE6 that were previously unseen.

A new approach to automation of chemical synthesis
Researchers have used a robotic platform to produce -- with no physical intervention -- three pharmaceutical compounds with yields and purities comparable to those achieved by manual efforts, they say.

Breakthrough for treatment of fibrotic diseases
A drug combination has potential to halt a process responsible for large numbers of deaths.

Irreversible damage to color vision linked to popular erectile dysfunction drug
In a first-of-its-kind study, Mount Sinai researchers have shown that color vision problems caused by retinal damage on a cellular level can result from a high dose of sildenafil citrate, the popular erectile-dysfunction medication sold under the brand name Viagra.

Study reveals Viagra to be 'ineffective' for fetal growth restriction
A University of Liverpool led international clinical trial has found an anti-impotence drug to be ineffective at improving outcomes for pregnancies complicated by fetal growth restriction.

Sildenafil should be avoided in valve disease with residual pulmonary hypertension
Sildenafil should not be used to treat residual hypertension in patients with valvular heart disease, according to late-breaking results from the SIOVAC trial presented today in a Hot Line LBCT Session at ESC Congress.

Read More: Sildenafil News and Sildenafil Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.